Skip to main content
OpenTrials
Completed

NCT Number: NCT00372307

Efficacy and Safety of Pimecrolimus for the Treatment of Vitiligo Vulgaris

Patients with vitiligo vulgaris are treated with Pimecrolimus twice a day during 6 months. After a baseline visit, patient returns for a control visit after 3 and 6 months of treatment. One reference lesion is clinically evaluated with pictures.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Vitiligo Vulgaris Hypopigmentation Pigmentation Disorders Skin Diseases Skin and Connective Tissue Diseases Vitiligo

Age range

6 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

University Hospital Ghent

Ghent, 9000, Belgium

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Active or stable vitiligo vulgaris
  • lesions at head or neck + maximum 10% lesions at the rest of the body

Exclusion criteria

  • Topica during last 2 weeks
  • Photo(chemo)therapy during last 4 weeks
  • Segmentary vitiligo

Treatment and study plan

Application of pimecrolimus

Drug

Primary outcomes

  1. Repigmentation percentage of the reference lesion after 6 months.

Secondary outcomes

  1. Number of patients with repigmentation after 3 and 6 months.

  2. Repigmentation percentage of the reference lesion after 3 months.

  3. Adverse events (month 3 and 6).

Sponsors and collaborators

Lead sponsor

University Hospital, Ghent

Other

Collaborators

  • Novartis

Registry information

Important dates

Study start
2004
Study completion
2004
First posted
Sep 6, 2006
Registry last updated
Dec 28, 2007

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.